Comparable stake leader
Sanofi
SEC ownership of Innate Pharma SA
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001598599.
Disclosed value leader
Lion Point Capital, LP
Comparable rows
3/12
Latest evidence
31 Mar 2026
- Public ticker
- IPHA on Nasdaq, IPHYF on OTC
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Sanofi
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 12
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Sanofi
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001598599
- Issuer location
- Marseille
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Innate Pharma SA (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Sanofi
Disclosed value leader
Lion Point Capital, LP
Comparable rows
3/12
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 9%
9 rows are not safely comparable across share classes.
13D/G row: Sanofi
Showing 1-8 of 12 holder rows.
Quick read
Sanofi leads the comparable SEC ownership view at 9%.
3 of 12 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Sanofi's linked filing trail.
Comparable ownership
Top 3
Sanofi
9%
ASTRAZENECA PLC
8.3%
Bpifrance Participations SA
7.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 12 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sanofi |
13D/G
|
9%
|
—
8,345,387 shares
|
$0 | 23 Apr 2025 |
| ASTRAZENECA PLC |
13D/G
|
8.3%
|
—
7,825,501 shares
|
$0 | 22 Dec 2025 |
| Bpifrance Participations SA |
13D/G
Caisse des depots et consignations
|
7.9%
|
—
7,319,429 shares
|
$0 | 25 Apr 2025 |
| Lion Point Capital, LP |
13F
Company
|
—
class O/S missing
|
$103,873
81,151 shares
|
— | 31 Mar 2026 |
| MORGAN STANLEY |
13F
Company
|
—
class O/S missing
|
$55,711
43,524 shares
|
— | 31 Mar 2026 |
| JANE STREET GROUP, LLC |
13F
Company
|
—
class O/S missing
|
$55,507
43,365 shares
|
— | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$12,882
10,064 shares
|
— | 31 Mar 2026 |
| RHUMBLINE ADVISERS |
13F
Company
|
—
class O/S missing
|
$6,057
4,734 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 24 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Recent insider transactions for Innate Pharma SA
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.